

Docket No. PHUS-28

REMARKS

Claims 11-15, 18-37, and 49-56 remain pending herein. Claims 11-15, 18-37 and 49-56 have been amended. Claims 1-10, 16-17, and 38-48 were previously canceled. No new claim has been added. Reconsideration of the claims as pending is respectfully requested.

Applicants acknowledge with appreciation the courtesies extended by Examiner to the undersigned during the telephone interview of January 5, 2005 during which the status of the claims as of the filing of the Amendment dated October 1, 2004 was discussed. It was agreed that claim 49 and its dependent claims would be rewritten to cover a pharmaceutical composition, which encompasses the embodiment of a pharmaceutical dosage form. It was agreed that grammatical changes would be made to claims 52-54. It was also agreed that all instances, in the claims, of the term "subject" would be replaced with the term "mammal". Applicants have amended the claims as agreed to with Examiner.

Claims 11-15, 18-37, and 49-56 are amended herein by changing their preamble to recite a "composition" as opposed to a "dosage form", it being understood and agreed upon with Examiner that the term "composition" encompasses within its scope the term "dosage form" among other compositions.

Claims 18, and 22-24 are amended herein by replacing the term "subject" with "mammal".

Claims 53 and 54 are amended herein to make grammatical changes, it being understood that the claims still cover embodiments defining aspects relating to the COX-II inhibitor, pridinol or both. For example, claim 53 concerns the COX-II inhibitor, pridinol or both.

Applicants respectfully submit that no new matter has been added by way of these amendments as they are fully supported by the specification as filed.

Examiner has requested that Applicant provide a suggested order of claims for reorganization and renumbering prior to issuance. The attached document includes a table correlating the current claim number and order and the proposed new claim number and order.

Entry of the amendments indicated herein and in the "Amendments to the Claims" into the record is requested.

Docket No. PHUS-28

To the knowledge of the Applicants, all rejections and objections have been overcome or otherwise withdrawn. In view of all the foregoing, Applicants respectfully submit that the pending claims are patentable over the art of record and in form for allowance. An early notice of allowance thereof is requested.

Respectfully submitted,

Date: 1/6/5

Innovar, L.L.C.
P.O. Box 250647
Plano, TX 75025-0647
Ph.: 972-747-7373
Fax: 972-747-7375



Rick Mates, Ph.D.
Registration No. 40,082
Agent for Applicant
Email: innovarllc@sbcglobal.net